Cipla is currently trading at Rs 309.05, up by 2.15 points or 0.70% from its previous closing of Rs 306.90 on the BSE.
The scrip opened at Rs 307.50 and has touched a high and low of Rs 310.80 and Rs 306.00 respectively. So far 167166 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 380.80 on 04-Jan-2011 and a 52 week low of Rs 273.60 on 06-Sep-2011.
Last one week high and low of the scrip stood at Rs 310.80 and Rs 284.00 respectively. The current market cap of the company is Rs 24641.66 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 33.43% and 29.62% respectively.
India’s second largest drug maker by domestic sales, Cipla has reported a jump of 17.44% in its standalone net profit at Rs 308.97 crore for the second quarter ended September 30, 2011 on increased sales and cost savings. The company had posted a net profit of Rs 263.08 crore in the July-September quarter of the previous fiscal.
Total income of the company also rose by 9.16% to Rs 1802.33 crore during the reporting quarter from Rs 1651.03 crore in the year-ago period.
Exports to Africa were up 41% and the firm benefited from operational efficiencies in material consumption and product mix. Cipla’s sales in the domestic market grew on expected lines by 12%. Sales in Middle East were affected by changed market circumstances.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.20 |
| Dr. Reddys Lab | 1235.00 |
| Cipla | 1232.20 |
| Zydus Lifesciences | 936.50 |
| Lupin | 2331.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: